Why This Seemingly ‘Great Deal’ Pharma Stock Is Contraindicated
With a massive cash balance (and no debt), rapidly growing revenue and earnings, and a well-stocked pipeline, the pharma stock that’s the focus of today’s…
With a massive cash balance (and no debt), rapidly growing revenue and earnings, and a well-stocked pipeline, the pharma stock that’s the focus of today’s…
While the broader market has been all over the place over the past few months, one area that has performed significantly better than the S&P…
Looking for “exciting biotech plays that won’t break the bank”? Today’s article highlights three such plays, all of which are trading under $3 per share,…
The small-cap biotech highlighted in today’s article has had mixed clinical results when it comes to one of its novel cancer immunotherapy candidates. The author,…
Heightened volatility across most asset classes over the last two months has led to a surge in trading volumes – and to exchange stocks (the…
Some sectors are holding up much better than others in the current market environment – and offering compelling plays in the process. One of those…
After three straight months of losses, April brought the S&P 500 health care sector its best one-month gain in twenty years, and today’s article notes…
If you need any further evidence of just how much the COVID-19 pandemic has increased the allure of biotechnology stocks, consider the little-known Chinese biotech…
In the world of penny stocks, biotech penny stocks and energy penny stocks have been among the big movers recently – and the author of…
In assessing the current market environment, the author of today’s article notes that “it becomes apparent that there’s an opportunity for those able to take…